Zacks Investment Research upgraded shares of Xeris Pharmaceuticals (NASDAQ:XERS) from a hold rating to a buy rating in a research note published on Saturday morning, Zacks.com reports. Zacks Investment Research currently has $6.00 price objective on the stock.
According to Zacks, “Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company’s proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. “
A number of other research analysts have also recently weighed in on the stock. ValuEngine raised shares of Xeris Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Saturday, May 30th. Mizuho reaffirmed a buy rating and issued a $14.00 target price on shares of Xeris Pharmaceuticals in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Xeris Pharmaceuticals has a consensus rating of Buy and an average target price of $11.40.
Shares of XERS opened at $2.66 on Friday. The company has a debt-to-equity ratio of 2.16, a current ratio of 4.82 and a quick ratio of 4.72. The firm has a 50 day simple moving average of $4.59 and a 200-day simple moving average of $4.36. Xeris Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $12.94. The stock has a market cap of $94.35 million, a price-to-earnings ratio of -0.58 and a beta of 2.10.
Xeris Pharmaceuticals (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.89) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative net margin of 3,100.00% and a negative return on equity of 323.82%. The business had revenue of $1.68 million during the quarter, compared to analysts’ expectations of $1.82 million. On average, equities analysts expect that Xeris Pharmaceuticals will post -3.06 earnings per share for the current fiscal year.
In related news, insider John Patrick Shannon, Jr. purchased 22,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $3.55 per share, for a total transaction of $78,100.00. Following the acquisition, the insider now directly owns 117,493 shares in the company, valued at $417,100.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul R. Edick purchased 33,000 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was bought at an average price of $3.54 per share, for a total transaction of $116,820.00. Following the acquisition, the insider now owns 95,493 shares in the company, valued at $338,045.22. The disclosure for this purchase can be found here. 5.95% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace North America L.P. acquired a new position in shares of Xeris Pharmaceuticals in the 1st quarter valued at $71,000. Tower Research Capital LLC TRC lifted its holdings in shares of Xeris Pharmaceuticals by 1,381.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,793 shares of the company’s stock valued at $55,000 after acquiring an additional 7,267 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Xeris Pharmaceuticals during the 1st quarter valued at $26,000. Deutsche Bank AG lifted its holdings in shares of Xeris Pharmaceuticals by 40.7% during the 1st quarter. Deutsche Bank AG now owns 13,617 shares of the company’s stock valued at $27,000 after acquiring an additional 3,942 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Xeris Pharmaceuticals during the 1st quarter valued at $33,000. Institutional investors own 62.48% of the company’s stock.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Story: How does the Beige Book influence monetary policy?
Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.